AB
AEON BiopharmaClinical-stage biopharmaceutical company developing ABP-450 (prabotulinumtoxinA), a biosimilar to Botox, for therapeutic indications like cervical dystonia and chronic migraine.
1 Pulse story
TB
Triveni BioTriveni Bio develops genetics-informed antibody and bispecific therapeutics for immunological and inflammatory diseases.
2 Pulse stories
Total Raised
$272M
AEON BiopharmaTriveni Bio
Last ValuationNot disclosed
Biotech
Sector
Biotech
2013
Founded
2023
Irvine, California
HQ
Waltham, Massachusetts
Public (AEON)
Status
Private
AEON Biopharma investors
No investors on record.
Triveni Bio investors
Atlas VentureCormorant Asset ManagementAscenta CapitalJanus Henderson InvestorsDeep Track CapitalOrbiMedViking Global InvestorsFidelity Management & Research
Data from Value Add Pulse coverage and company research — see the full threads for AEON Biopharma and Triveni Bio.